The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2026 | The value of rapid and reliable manufacturing in the CAR-T process
In this video, Leyre Bento De Miguel, MD, Son Espases University Hospital, Palma de Mallorca, Spain, briefly discusses the importance of rapid and reliable manufacturing in the CAR T-cell therapy process for diffuse large B-cell lymphoma (DLBCL), highlighting that shorter manufacturing times can greatly impact patient outcomes, particularly for those with aggressive disease. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in the symposium last week, we talked about the speed and about the manufacturing. We have like one part only for talking about this. And I think that is, as I said before, it’s a really critical point. I mean, the rapid and reliable manufacturing means that the time will be shorter. So in this kind of patient with diffuse large cell lymphoma, that is really aggressive and that can be like a faster, I mean, a really aggressive disease in a really short time...
So in the symposium last week, we talked about the speed and about the manufacturing. We have like one part only for talking about this. And I think that is, as I said before, it’s a really critical point. I mean, the rapid and reliable manufacturing means that the time will be shorter. So in this kind of patient with diffuse large cell lymphoma, that is really aggressive and that can be like a faster, I mean, a really aggressive disease in a really short time. This waiting time is really important to be as short as we can because during, after the apheresis, we need to to control the disease with a bridging therapy or radiotherapy or whatever. But sometimes it’s really difficult to control. And sometimes, unfortunately, the patients can’t wait and can arrive at infusion. So the manufacturing, I mean, the rapid manufacturing and reliable manufacturing, I think that could be really, really important.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
